Novasecta Networking Breakfasts
In 2024, Novasecta hosted two networking breakfasts for our pharmaceutical network in Copenhagen. The events were attended by senior representatives from a range of pharmaceutical companies, who brought diverse perspectives on the topics we discussed. On 9th April 2024, we discussed ‘Success in Pharma’, with a focus on how companies achieve long-term success through: […]
The Novasecta European MidPharma Report 2024
Europe is home to 98 ‘MidPharmas’: companies that research, develop, and commercialise pharmaceutical products with €100m-€10bn annual revenue. In our 2024 European MidPharma report, we examine the 2023 performance of European-headquartered MidPharmas and contrast it to Big Pharma. We then explore the success drivers that enable MidPharmas to thrive. What to Expect in the Report This year’s report […]
A Robust Partnering Strategy
Challenge A European mid-Pharma company had a gap in its pipeline and was looking for support in forming partnerships to sustain profitable growth in the medium term The BD strategy needed to build upon the company’s recent successful commercialisation of a large molecule and a profitable portfolio of branded mature products Solution Interviewed the Global […]
Agile Operational Governance to Optimise Asset Decision-making
Challenge Changes to the R&D organisational structure and strategic governance process created a need to review and optimise governance at a project level There was appetite to simplify the current R&D operational governance model, reinforce project team empowerment and embed agility within the operational governance model Solution Interviewed more than 40 key stakeholders to […]
Enhancing R&D productivity in MidPharma
On the 24th and 25th April, we had the pleasure of hosting our annual face-to-face MidPharma R&D Symposium in London, the first since the COVID-19 pandemic. The event began with a networking dinner on the evening of the 24th followed by facilitated discussions on the 25th. The symposium was attended by 13 R&D Leaders from […]
What it takes to leverage AI in pharma and biotech R&D
In March 2024 John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of (Artificial Intelligence) AI for their Research and Development (R&D) efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and […]
5 Imperatives for Strategic And Operational Excellence: #1 Strategic Focus
Developing and maintaining a sharp strategic focus is a must for strategic and operational excellence in pharma and biotech. In part one of our series ‘The Five Imperatives of Strategic and Operational Excellence’, we explore why strategic focus is important, what good looks like, and how a sharp strategic focus contributes to strategic and operational […]
Novo Nordisk showed ‘extraordinary growth’ but faces competitive weight loss market (CNBC)
John Rountree, Managing Partner at Novasecta, comments on Danish pharma giant Novo Nordisk’s first-quarter earnings. Watch John’s interview here.
Data deals for an AI biotech
Challenge An AI drug discovery biotech sought drug discovery data from both failed and successful assets to train its algorithms. Management wanted to understand MidPharma appetite for and concerns over providing their drug discovery data in creative deal structures, so that it could consider how to further evolve its data strategy. Solution Engaged with the […]